Skip to main content
SpringerLink
Log in

PET/CT: Is There a Role?

  • Chapter
  • First Online:
Imaging in Clinical Oncology

  • 2760 Accesses

Abstract

PET/CT co-registered with MRI plays a significant role in the management of gliomas and brain metastases from other tumors. The available radiopharmaceuticals are indices of glucose metabolism, amino acid transport, proliferation rate of tumor cells and hypoxia respectively. FDG and FLT are useful in grading and prognosis and amino acids MET, FET and FDOPA in the delineation of the tumor, especially of low grade gliomas, the differentiation between low and high grade gliomas and between recurrence and necrosis post therapy, as well as in radiotherapy planning and treatment efficacy assessment. Tracers of hypoxia demonstrate hypoxic tumor areas of radioresistance which need additional treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Afshar-Oromieh A, Giesel FL, Linhart HG et al (2012) Detection of cranial meningiomas: comparison of 68 Ga-DOTATOC PET/CT and contrast enhanced MRI. Eur J Nucl Med Mol Imaging 39:1409–1415

    Article  PubMed  Google Scholar 

  2. La Fougère C, Suchorska B, Bartenstein P et al (2011) Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-Oncology 13:806–819

    Article  PubMed  Google Scholar 

  3. Heiss P, Mayer S, Herz M et al (1999) Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-l-tyrosine in vitro and in vivo. J Nucl Med 40:1367–1373

    PubMed  CAS  Google Scholar 

  4. Chen W, Silverman DH, Delaloye S et al (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911

    PubMed  CAS  Google Scholar 

  5. Chen W, Cloughesy T, Kamdar N et al (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46:945–952

    PubMed  CAS  Google Scholar 

  6. Kwee SA, Ko JP, Jiang CS et al (2007) Solitary brain lesions enhancing at MR imaging: evaluation with fluorine18 fluorocholine PET. Radiology 244:557–565

    Article  PubMed  Google Scholar 

  7. Swanson KR, Chakraborty G, Wang CH et al (2009) Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 50:36–44

    Article  PubMed  Google Scholar 

  8. Lendvai G, Estrada S, Bergström M et al (2009) Radiolabelled oligonucleotides for imaging of gene expression with PET. Curr Med Chem 16:4445–4461

    Article  PubMed  CAS  Google Scholar 

  9. Battle MR, Goggi JL, Allen L et al (2011) Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled ανbeta3-integrin and ανbeta5-integrin imaging agent. J Nucl Med 52:424–443

    Article  PubMed  CAS  Google Scholar 

  10. Iagaru A, Mosci E, Mittra S et al (2012) ανβ3 integrins as a biomarker of disease recurrence in glioblastoma multiforme: initial clinical results using 18F FPPRGD2 PET/CT. Εur J Nucl Med Mol Imaging 39(2):S244–S245 (abstract)

    Google Scholar 

  11. Allen AM, Ben-Ami M, Reshef A et al (2012) Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10. Eur J Nucl Med Mol Imaging 39:1400–1408

    Article  PubMed  Google Scholar 

  12. Goldman S, Levivier M, Pirotte B et al (1997) Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38:1459–1462

    PubMed  CAS  Google Scholar 

  13. Yamaguchi S, Kobayashi H, Hirata K et al (2011) Detection of histological anaplasia in gliomas with oligodendroglial components using positron emission tomography with (18)F-FDG and (11)C-methionine: report of two cases. J Neurooncol 101:335–341

    Article  PubMed  Google Scholar 

  14. Pirotte B, Goldman S, Massager N et al (2004) Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45:1293–1298

    PubMed  CAS  Google Scholar 

  15. Becherer A, Karanikas G, Szabó M et al (2003) Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 30:1561–1567

    Article  PubMed  CAS  Google Scholar 

  16. Kunz M, Thon N, Eigenbrod S et al (2011) Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 13:307–316

    Article  PubMed  CAS  Google Scholar 

  17. Dunet V, Rossier C, Buck A et al (2012) Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med 53:207–214

    Article  PubMed  CAS  Google Scholar 

  18. Chen W, Cloughesy T, Kamdar N et al (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46:945–952

    PubMed  CAS  Google Scholar 

  19. Nariai T, Tanaka Y, Wakimoto H et al (2005) Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498–507

    Article  PubMed  Google Scholar 

  20. Barker FG 2nd, Chang SM, Huhn SL et al (1997) Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80:936–941

    Article  PubMed  Google Scholar 

  21. Law M, Yang S, Wang H et al (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989–1998

    PubMed  Google Scholar 

  22. Pirotte BJ, Lubansu A, Massager N et al (2007) Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg 107:392–399

    Article  PubMed  Google Scholar 

  23. Ling CC, Humm J, Larson S et al (2000) Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47:551–560

    Article  PubMed  CAS  Google Scholar 

  24. Lee IH, Piert M, Gomez-Hassan D et al (2009) Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73:479–485

    Article  PubMed  CAS  Google Scholar 

  25. Grosu AL, Weber WA, Franz M et al (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519

    Article  PubMed  CAS  Google Scholar 

  26. Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461

    Article  PubMed  Google Scholar 

  27. Shah R, Vattoth S, Jacob R et al (2012) Radiation necrosis in the brain: imaging features and differentiation from tumor recurrence. Radiographics 32:1343–1359

    Article  PubMed  Google Scholar 

  28. Rachinger W, Goetz C, Pöpperl G et al (2005) Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57:505–511 (discussion 505–511)

    Google Scholar 

  29. Wardak M, Schiepers C, Dahlbom M et al (2011) Discriminant analysis of 18F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res 17:6553–6562

    Article  PubMed  CAS  Google Scholar 

  30. Chen W, Delaloye S, Silverman DH et al (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714–4721

    Article  PubMed  CAS  Google Scholar 

  31. Galldiks N, Rapp M, Stoffels G et al (2012) Response assessment of bevacizumab in patients with recurrent malignant glioma using [(18)F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 2012 [Epub ahead of print]

    Google Scholar 

  32. Battle MR, Goggi JL, Allen L et al (2011) Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled ανbeta3-integrin and αV beta5-integrin imaging agent. J Nucl Med 52:424–430

    Article  PubMed  CAS  Google Scholar 

  33. Horky LL, Hsiao EM, Weiss SE et al (2011) Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol 103:137–146

    Article  PubMed  Google Scholar 

  34. Dittmann H, Dohmen BM, Paulsen F et al (2003) [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 30:1407–1412

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Physics, Medical School, University of Athens, 75 Mikras Asias, Goudi, 115 27, Athens, Greece

    Julia V. Malamitsi

Authors
  1. Julia V. Malamitsi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia V. Malamitsi .

Editor information

Editors and Affiliations

  1. University of Athens, Greece, Athens, Greece

    Athanasios D. Gouliamos

  2. Hygeia and Mitera Hospital, Athens, Greece

    John Andreou

  3. Hygeia Hospital, Athens, Greece

    Paris Kosmidis

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Malamitsi, J.V. (2014). PET/CT: Is There a Role?. In: Gouliamos, A., Andreou, J., Kosmidis, P. (eds) Imaging in Clinical Oncology. Springer, Milano. https://doi.org/10.1007/978-88-470-5385-4_20

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5385-4_20

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5384-7

  • Online ISBN: 978-88-470-5385-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation